Eisai Co., Ltd.｜A Human Health Care Company

• January 30World NTD (Neglected Tropical Disease) Day

  Eisai is working on elimination of NTDs with global partners.*Photo ©JICA

  Learn more

  

  January 30World NTD (Neglected Tropical Disease) Day

  Eisai is working on elimination of NTDs with global partners.*Photo ©JICA

  Learn more

• Value Creation Report 2025

  Learn more

  

  Value Creation Report 2025

  Learn more

• Human Capital Report 2025

  Learn more

  

  Human Capital Report 2025

  Learn more

• Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

  Learn more

  

  Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

  Learn more

• 

  Second Quarter Financial Results FY2025

• 

  Recent hhc Activities “Let‘s Learn More about Cancer Patients”

• 

  Overview of Eisai's Initiatives for Dementia

• 

  Sustainability Article: Transportation of Investigational Drugs for Mycetoma During Armed Conflict

• News Release
• Latest News
• Information

• January 26, 2026
  • R&D
  • Products

  FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under priority ReviewIf approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May 24, 2026

• January 21, 2026
  • Corporate
  • Sustainability

  EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE TENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

• January 13, 2026
  • Corporate
  • R&D

  Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and JapanEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, the Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaNuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to €195 million (approx. USD $230 million) in upfront and milestone payments Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer

• January 13, 2026
  • Corporate

  Changes of Corporate Officers

• January 6, 2026
  • R&D
  • Products

  Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in ChinaIf approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease

View All

• December 22, 2025

  Sustainability “Transportation of Investigational Drugs for Mycetoma During Armed Conflict ー A Year and a Half of Effort With the Dedication of Many Stakeholders to Complete Shipment”

• November 21, 2025

  Sustainability “Call for Support of Japanese Corporate Activities and ODA in the Global Health Sector ー Letter of Request Delivered to Mr. Toshimitsu Motegi, Minister of Foreign Affairs”

• November 5, 2025

  IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2026 (Material, Webcast)”

• November 5, 2025

  IR “Second Quarter Financial Reports for the Fiscal Year Ending March 31, 2026”

View All

• November 25, 2025

  Notice on Discontinuation of Receiving Emails with Password-Protected Attachments

• February 19, 2025

  Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”

• October 3, 2024

  EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024

• June 21, 2024

  Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”

• June 3, 2024

  The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”

View All

Sustainability

32 countries 2.68billion tablets

Number of countries supplied with lymphatic filariasis treatment and volume supplied (as of September 2025)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

• Message from Top Management
• Eisai's Sustainability
• Sustainability Management
• Initiatives for Improving Access to Medicines
• Environmental
• Society
• Governance
• ESG Data & Report

Sustainability TOP

• 

  Improving Access to Medicines TOP

• 

  Initiatives for Elimination of Neglected Tropical Diseases

• 

  Initiatives for Improving Access to Medicines for Non-communicable Diseases

• 

  Research & Development for Improving Access to Medicines

• 

This website uses cookies to enhance your browsing experience. By using this site, you agree to our use of cookies. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Please refer to the “External Data Transmission” section for further information.

close